Search Within

Jagrutiben Chaudhari

Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (6)
  2. Hematologic Malignancies, Division of (6)
  3. Center for Hematologic Malignancies (5)
  4. Hematologic Malignancies Research (5)
  5. Bone Marrow Transplant (4)
  6. GSK Faculty (4)

More Groups

People
  1. Xiuyan Wang (6)
  2. Isabelle Riviere (5)
  3. Devin Mcavoy (3)
  4. Jolanta Stefanski (3)
  5. Kinga Hosszu (3)
  6. Sergio Giralt (3)

More People

Years
  1. 2025 (2)
  2. 2024 (1)
  3. 2022 (1)
  4. 2021 (1)
  5. 2019 (1)
  6. 2018 (1)
Publications
  1. Molecular Therapy (2)
  2. Blood Advances (1)
  3. Clinical Lymphoma, Myeloma and Leukemia (1)
  4. Journal of Clinical Oncology (1)
  5. Molecular Therapy - Methods & Clinical Development (1)
  6. iScience (1)
Publishers
  1. Nature Publishing Group (3)
  2. American Society of Clinical Oncology (1)
  3. American Society of Hematology (1)
  4. Cell Press (1)
  5. Elsevier Inc. (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
    Journal Article

    Shahid, S.; Prockop, S. E.; Flynn, G. C.; Mauguen, A.; White, C. O.; Bieler, J.; McAvoy, D.; Hosszu, K.; Cancio, M. I.; Jakubowski, A. A.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Activation of mitochondrial TRAP1 stimulates mitochondria-lysosome crosstalk and correction of lysosomal dysfunction
    Journal Article

    Chen, F. W.; Davies, J. P.; Calvo, R.; Chaudhari, J.; Dolios, G.; Taylor, M. K.; Patnaik, S.; Dehdashti, J.; Mull, R.; Dranchack, P.; more...
    iScience (2022)

    Fulltext@MSK | Save
  • Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing
    Journal Article

    Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Du, F.; Qu, J.; Chaudhari, J.; Thummar, K.; Zhu, M.; Shen, L. B.; Hall, M.; more...
    Molecular Therapy - Methods & Clinical Development (2021)

    Fulltext@MSK | Save
  • CAR-T cell manufacturing with CliniMACS Prodigy
    Meeting Abstract

    Wang, X.; Stefanski, J.; Chaudhari, J.; Hall, M.; Thummar, K.; Zhao, Z.; Sadelain, M.; Riviere, I.
    Molecular Therapy (2019)

    Fulltext@MSK | Save
  • CAR-T cell manufacturing with CliniMACS Prodigy
    Meeting Abstract

    Wang, X.; Stefanski, J.; He, Q.; Chaudhari, J.; Hack, A.; Riviere, I.
    Molecular Therapy (2018)

    Fulltext@MSK | Save